scout

Shorts

In a conversation with CancerNetwork® at the 3rd Biennial Miami Precision Medicine Conference, Craig H. Moskowitz, MD, discussed the gradually diminishing role that autologous stem cell transplant (ASCT) is playing in the modern lymphoma landscape with the rise of novel treatment modalities.
0:56
Autologous Stem Cell Transplantation is Having a “Slow Death” in Lymphoma
11 hours ago
by
Craig H. Moskowitz, MD
According to Jeff P. Sharman, despite displaying a profound impact on solid tumors, immune checkpoint inhibition has not been explored robustly in lymphomas.
0:43
Is There a Future for Immune Checkpoint Inhibition in Lymphoma?
15 hours ago
by
Jeff P. Sharman, MD
In a discussion with CancerNetwork®, Miranda Gogishvili, MD, spoke about updated efficacy data from the phase 3 EMPOWER-Lung 1 trial (NCT03088540) that she and colleagues presented at the 2026 European Lung Cancer Congress.
0:58
EMPOWER-Lung 1 Shows “Significant Milestone” for Cemiplimab in NSCLC
2 days ago
by
Miranda Gogishvili, MD
Alexander Z. Wei, MD, discussed strategies clinicians use to reduce the burden of surgery and preserve quality of life among patients with advanced urothelial cancers.
1:17
Highlighting Bladder Preservation Among Vulnerable MIBC Populations
3 days ago
by
Alexander Z. Wei, MD
Why mRNA Vaccines Change the Melanoma Game
0:46
Why mRNA Vaccines Change the Melanoma Game
3 days ago
by
Jamin C. Morrison, MD
Mina Fam, MD, compared the adverse effect profile of HIFU with other standards in the localized prostate cancer space.
0:45
Comparing HIFU To Surgery and SBRT in Localized Prostate Cancer
3 days ago
by
Mina Fam, MD
Benjamin Cooper, MD, spoke with CancerNetwork® about the mechanism of JNJ-1900, an investigational nanoparticle radioenhancer, as a treatment for patients with unresectable stage III non–small cell lung cancer as part of the phase 2 CONVERGE trial (NCT06667908).
0:51
Novel Radioenhancer May Help Prevent Disease Recurrence in Stage III NSCLC
4 days ago
by
Benjamin Cooper, MD
Why Are Younger Women Getting Diagnosed With Breast Cancer?
1:00
Why Are Younger Women Getting Diagnosed With Breast Cancer?
5 days ago
by
Shari B. Goldfarb, MD
In a conversation with CancerNetwork®, Nicole Lamanna, MD, discussed the potential role of minimal residual disease (MRD) as a tool for informing treatment strategies in chronic lymphocytic leukemia (CLL) management.
0:54
Can MRD Influence Therapy Duration in Chronic Lymphocytic Leukemia?
5 days ago
by
Nicole Lamanna, MD
In a discussion with CancerNetwork®, Nicolas Girard, MD, PhD, highlighted findings from the PALOMA-2 study (NCT05498428) that he and colleagues presented at the 2026 European Lung Cancer Congress.
0:53
PALOMA-2 Shows Benefits of Subcutaneous Amivantamab in EGFR+ NSCLC
7 days ago
by
Nicolas Girard, MD, PhD
Jeff P. Sharman, MD, identified ways to help expand access to bispecific antibodies among patients with diffuse large B-cell lymphoma.
1:25
Overcoming Institutional Barriers to Bispecific Antibody Access in DLBCL
8 days ago
by
Jeff P. Sharman, MD
Karie Runcie, MD, provided next steps for improving outcomes in genitourinary cancers, specifically related to kidney cancer.
0:38
Leveraging Neoadjuvant Strategies to Bolster Cure Rates in Kidney Cancer
9 days ago
by
Karie Danielle Keera Runcie, MD
A recent study that found 10.6% of patients developed a new mental health disorder within 1 year of their cancer diagnosis.
1:16
What New Tools Can Improve Mental Health Screening in Cancer Care?
9 days ago
by
Julian C. Hong, MD, MS
Karie Runcie, MD, highlighted research she conducted as part of the phase 2 Cyto-KIK trial, a single-arm study assessing cabozantinib and nivolumab in metastatic kidney cancer prior to cytoreductive nephrectomy.
0:49
Cabozantinib Combo Displays Feasibility in Metastatic Kidney Cancer Group
10 days ago
by
Karie Danielle Keera Runcie, MD
Oxybutynin offered comparable ‘speed-to-relief’ vs comparators among patients experiencing hot flashes while on androgen deprivation therapy for prostate cancer, according to Bradley J. Stish, MD.
0:44
Offering Rapid Relief of Treatment-Emergent Hot Flashes in Prostate Cancer
11 days ago
by
Bradley J. Stish, MD
Following the FDA approval of teclistamab-cqyv (Tecvayli) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro) for patients with relapsed/refractory multiple myeloma, María-Victoria Mateos, MD, PhD, spoke with CancerNetwork® about how findings from the phase 3 MajesTEC-3 trial (NCT05083169) support the regimen’s clinical utility.
0:45
Teclistamab/Daratumumab: An Exciting Combination in R/R Multiple Myeloma
15 days ago
by
Maria-Victoria Mateos, MD, PhD
Despite accounting for less than 1% of prostate cancer diagnoses, neuroendocrine prostate cancer (NEPC) is associated with suboptimal outcomes in the space, according to Rahul Aggarwal, MD.
0:49
Highlighting an Unmet Need in Neuroendocrine Prostate Cancer
16 days ago
by
Rahul R. Aggarwal, MD
The phase 3 CHALLENGE trial established a significant survival advantage among patients with colorectal cancer who underwent a structured exercise program, according to Linda Carlson, PhD, RPsych.
1:05
Could Exercise Be Prescribed as a Standard of Care for Cancer Treatment?
16 days ago
by
Linda E. Carlson, PhD
In a discussion with CancerNetwork®, Guenther Koehne, MD, highlighted the rapid development of therapeutic options in the multiple myeloma field, which has seen an increase in novel immunotherapies and a decrease in the use of chemotherapy.
0:48
Is a Functional Cure Possible in Multiple Myeloma Therapy?
17 days ago
by
Guenther Koehne, MD
Care Coordination Experiences in Breast Cancer
0:30
Care Coordination Experiences in Breast Cancer
18 days ago
by
Nicole Arrato, PhD
Joaquim Bellmunt, MD, PhD, discussed the emergence of EVP as a standard of care regardless of fitness among all cisplatin-eligible MIBC populations.
1:21
Affirming Enfortumab Vedotin/Pembrolizumab as a Standard Across MIBC Groups
18 days ago
by
Joaquim Bellmunt, MD, PhD
In a conversation with CancerNetwork®, Nicolaus Kröger, MD, detailed how JAK inhibition can work in tandem with transplantation to improve outcomes among patients with myelofibrosis.
0:35
JAK Inhibitors May Improve Transplantation Outcomes in Myelofibrosis
22 days ago
by
Nicolaus Kröger, MD
Joy Li, MD, discussed findings from a retrospective analysis of patients treated with enfortumab vedotin with or without pembrolizumab in the adjuvant setting for at least 2 cycles of treatment at the 2026 ASCO GU Symposium.
1:04
Should You Discontinue Therapy for Urothelial Carcinoma During Toxicity?
22 days ago
by
Joy Li, MD
Study Finds 80% of Young Cancer Survivors Face Sexual Dysfunction
0:34
Study Finds 80% of Young Cancer Survivors Face Sexual Dysfunction
23 days ago
by
Chiara Acquati, PhD, LMSW, FAOSW
Benjamin Garmezy, MD, discussed safe management practices for treatment-emergent adverse effects (TEAEs) with MRT-2359 plus enzalutamide in the treatment of androgen receptor ligand-binding domain-mutated metastatic castration-resistant prostate cancer.
0:49
Examining Optimal Management Strategies for MRT-2359 in LBD-Mutant CRPC
24 days ago
by
Benjamin Garmezy, MD
When Do New Mental Health Disorders Occur Most in Patients with Cancer?
1:07
When Do New Mental Health Disorders Occur Most in Patients with Cancer?
24 days ago
by
Julian C. Hong, MD, MS
Chemobrain Vs Dementia: Understanding the Difference
1:03
Chemobrain Vs Dementia: Understanding the Difference
24 days ago
by
Yesne Alici, MD
In a discussion with CancerNetwork®, Natalia Neparidze, MD, spoke about the importance of minimal residual disease (MRD) as a relevant end point for clinical trials assessing novel therapeutic strategies among patients with multiple myeloma.
0:40
MRD is ‘Exceedingly Helpful’ in Assessing Multiple Myeloma Disease Course
24 days ago
by
Natalia Neparidze, MD
After the FDA granted priority review to rusfertide as a potential therapeutic option for patients with polycythemia vera, CancerNetwork® spoke with Andrew Kuykendall, MD, about what a potential FDA approval would mean for these patients.
0:45
Rusfertide Approval Would Move Past ‘Archaic’ Polycythemia Vera Standard
25 days ago
by
Andrew T. Kuykendall, MD
Maha Hussain, MD, MBChB, discussed advantages associated with docetaxel-containing triplet regimens for this patients with metastatic HSPC following a Medical Crossfire session she was a presenter for.
1:22
Triplet Therapy Appears to Be Generally Well Tolerated in Metastatic HSPC
25 days ago
by
Maha Hussain, MD